2020 ESMO Update on ADCs in mTNBC: Is Sacituzumab Govitecan More Beneficial for OS & PFS Compared to Standard Chemotherapy?
By
ecancer
FEATURING
Aditya Bardia
By
ecancer
FEATURING
Aditya Bardia
Login to view comments.
Click here to Login
Videos